Investigational Diet Drug Has Staying Power, but Dieters Don't
15th Feb 2006, 04:09 GMT
NEW YORK - A daily dose of 20 mg of Acomplia (rimonabant), an investigational drug that fights fat by targeting a pleasure center in the brain, kept weight off study participants for two years and shrank inches off waistlines -- but half the study volunteers quit.
Investigational Diet Drug Has Staying Power, but Dieters Don't related news:
- SinuNase. IND on track — EurekAlert! - Business and Economics
- Debiopharm drug shows promise in HIV study — Pharmaceutical Business Review Online Latest News
- Insert asks FDA to permit clinical trials of cancer drug — Pharmaceutical Business Review Online Latest News
- Diet Decoder — thestar.com: Life Top Stories
- Cell Therapeutics Cancer Drug Fast Tracked — RedOrbit News - Health
- Diet-Pill-Review.com announces 125 consumer diet pill reviews. — PR Leap - Health News Releases
- Cheeseburgers or Salads? The Truth About Fat — RedOrbit News - Health
- What to do if your Valentine... is on a diet — Slashfood
- It takes more than a badge to gain respect — KeralaNext: Asia
- DS Lite diet facts — Joystiq
Latest news from MedPage Today Cardiovascular:
- AHA: Women Receive Less Cardiovascular Secondary Prevention
- AHA: Chest Protectors Have Fatal Flaws in Blocking Cardiac Arrest
- AHA: No Cardiovascular Benefit from Folic Acid and B Vitamins
- AHA: Attention from Pharmacist Improves Compliance for Older Patients
- AHA: Non-Invasive Office-Based Test Could Increase Appropriate Use of ICDs
- AHA: Human Atrial Natiuretic Peptide May Reduce Reperfusion Injury
- AHA: Blood Test Improves Management of Acute Heart Failure
- AHA: Novel Drug Effective for Hyponatremia in Heart Failure Patients